Compare BridgeBio Pharma Inc (BBIO) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Jumia Technologies AG - ADR — how do they compare? BridgeBio Pharma Inc trades at $84.78 (market cap $16.36B), while Jumia Technologies AG - ADR trades at $6.22 (market cap $719.58M). The key difference: BridgeBio Pharma Inc is far larger — about 22.7× Jumia Technologies AG - ADR's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| BBIO | JMIA | |
|---|---|---|
Market Cap | $16.36B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $14.60 |
52-Week Low | $47.29 | $5.69 |
Enterprise Value | $18.14B | $666.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
JMIA trades at $6.00, down 3.07% today, with a bearish technical signal. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Analyst sentiment is positive with 71% buy ratings, supported by progress toward Q4 2026 breakeven targets and recent $50M capital raise.
The path to profitability remains the key investment thesis, with management targeting 2027 EBITDA breakeven. Risks include persistent cash burn, competitive e-commerce landscape, and execution challenges in African markets. The stock offers speculative upside if turnaround continues but carries significant operational risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
